Cellular senescence is one of the most actively targeted hallmarks of aging. Senescent cells — sometimes called “zombie cells” — permanently exit the cell cycle without dying. Instead, they secrete a pro-inflammatory cocktail (the Senescence-Associated Secretory Phenotype, or SASP) that damages neighboring tissue, depletes stem cell niches, and drives chronic inflammation. Senolytics are drugs designed to selectively eliminate these cells while leaving healthy cells unharmed.
## The Mechanism of Selectivity
Senescent cells activate anti-apoptotic pathways (particularly BCL-2 family proteins, PI3K/AKT, and p21) to survive. This dependence on anti-apoptotic survival signals is a vulnerability: drugs that block these pathways preferentially kill senescent cells because normal cells rely on them less.
Senostatics, a related class, suppress SASP secretion without killing senescent cells. Rapamycin and JAK inhibitors are leading senostatic candidates.
## Key Senolytic Candidates
**Dasatinib + Quercetin (D+Q)**: The most studied combination. Dasatinib is an FDA-approved leukemia drug; quercetin is a natural flavonoid. Together they synergistically clear senescent cells across multiple tissues. Intermittent dosing (a few days per month rather than daily) appears sufficient and limits toxicity.
**Navitoclax (ABT-263)**: A BCL-2/BCL-XL inhibitor that potently clears senescent cells in mice but causes thrombocytopenia in humans. More selective derivatives are in development.
**Fisetin**: A flavonoid found in fruits and vegetables. Strong senolytic activity in animals, low toxicity, and ongoing human trials make it one of the most-watched natural compounds in geroscience.
## The Landmark Mouse Study
In 2015, Jan van Deursen’s team at Mayo Clinic published a Nature paper demonstrating that intermittently clearing senescent cells from naturally aging mice — beginning at middle age — extended median lifespan by approximately 35% and improved function in heart, kidney, and lung. Tumor incidence was also reduced. This result has since been replicated and extended by multiple groups. See [van Deursen Lab](https://www.mayo.edu/research/labs/van-deursen/overview).
## Human Trials
**Diabetic kidney disease (2019)**: The first human senolytic study, using D+Q on an intermittent schedule, showed significant reductions in senescence-related biomarkers in kidney tissue.
**Idiopathic pulmonary fibrosis (IPF)**: D+Q trials showed trends toward improved walking distance, pulmonary function, and quality of life, though sample sizes were small.
**Frailty**: Multiple RCTs are enrolling older adults with frailty to assess whether senolytic treatment improves physical function and reduces disability.
**Alzheimer’s disease**: Mayo Clinic and other groups are running senolytic trials for AD, based on animal evidence that clearing senescent microglia improves cognitive function.
Commercial development is advancing at Unity Biotechnology (joint tissue targets), Oisin Biotechnologies (gene-therapy-based senolysis), and Rejuvenation Bioscience.
## Prospects
Senolytics are mechanistically grounded in fundamental aging biology, not symptom management. If ongoing human RCTs replicate the animal results, they would represent a paradigm shift in geriatric medicine. Key trial readouts are expected between 2025 and 2030. For background, see [Hallmarks of Aging](https://sunqi.org/aging-biology-hallmarks-en/) and [Unity Biotechnology’s pipeline](https://unitybiotechnology.com/pipeline/).
—
